Unlike full growth hormone, AOD-9604 does not stimulate IGF-1 production or affect glucose metabolism, making it potentially safer for long-term joint support applications
The Company has 8,396,600 warrants outstanding from prior financings EMCs Position in the Company Emerging Markets Consulting participated directly in this financing by investing: CAD $671,356 Purchasing: 1,342,712 shares at CAD $0.50 per share, representing approximately 33.6% of the CAD $2,000,000 offering (Note: $671,356 of a $2,000,000 round is 33.6%.) In addition, we separately acquired: 1,000,000 additional shares through a private transaction EMCs total holding of 2,342,712 shares represents approximately 4.47% of the 52,431,207 common shares outstanding
It also supports angiogenesis and modulates inflammation
Mechanistically, R-ALA acts as a chelating agent due to its distinct dithiol structure, which contains two sulfur atoms